SIGILON THERAPEUTICS INC (SGTX) Stock Price, Forecast & Analysis
USA - NASDAQ:SGTX - US82657L2060 - Common Stock
SGTX Key Statistics, Chart & Performance
The current stock price of SGTX is 22.47 USD. In the past month the price increased by 4.95%. In the past year, price increased by 136.78%.
SGTX Latest News, Press Relases and Analysis
SGTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25.13 | 419.52B | ||
| AMGN | AMGEN INC | 15.76 | 185.54B | ||
| GILD | GILEAD SCIENCES INC | 15.53 | 157.86B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.31 | 112.67B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.62 | 74.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 882.84 | 59.02B | ||
| INSM | INSMED INC | N/A | 41.26B | ||
| NTRA | NATERA INC | N/A | 28.50B | ||
| BIIB | BIOGEN INC | 9.93 | 24.37B | ||
| INCY | INCYTE CORP | 16.68 | 20.91B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.7 | 21.13B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.42 | 14.69B |
Related stock screener links
About SGTX
Company Profile
Sigilon Therapeutics, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutic treatments for a wide range of chronic diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 62 full-time employees. The company went IPO on 2020-12-04. The firm is focused on developing functional cures for patients with acute and chronic diseases by providing stable and durable levels of therapeutic molecules to patients. The Company’s Shielded Living Therapeutics (SLTx) platform is comprised of two primary elements: the cells and the sphere. The Company’s lead product candidate, SIG-002, is designed to replace islet cells for the treatment of Type 1 Diabetes (T1D). The company is also developing product candidates for the treatment of lysosomal diseases. Its program for diabetes, it focused to apply the SLTx platform to develop product candidates, including product candidates for patients with liver and immune mediated diseases, and explore delivery of different molecules and alternative routes of administration. The company also engineers cells to express a therapeutic molecule of choice in a continuous manner, which it refers to as constitutive expression.
Company Info
SIGILON THERAPEUTICS INC
100 Binney Street, Ste 600
Cambridge MASSACHUSETTS US
Employees: 62
Phone: 16173367540.0
SIGILON THERAPEUTICS INC / SGTX FAQ
What does SIGILON THERAPEUTICS INC do?
Sigilon Therapeutics, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutic treatments for a wide range of chronic diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 62 full-time employees. The company went IPO on 2020-12-04. The firm is focused on developing functional cures for patients with acute and chronic diseases by providing stable and durable levels of therapeutic molecules to patients. The Company’s Shielded Living Therapeutics (SLTx) platform is comprised of two primary elements: the cells and the sphere. The Company’s lead product candidate, SIG-002, is designed to replace islet cells for the treatment of Type 1 Diabetes (T1D). The company is also developing product candidates for the treatment of lysosomal diseases. Its program for diabetes, it focused to apply the SLTx platform to develop product candidates, including product candidates for patients with liver and immune mediated diseases, and explore delivery of different molecules and alternative routes of administration. The company also engineers cells to express a therapeutic molecule of choice in a continuous manner, which it refers to as constitutive expression.
What is the stock price of SIGILON THERAPEUTICS INC today?
The current stock price of SGTX is 22.47 USD. The price decreased by -2.56% in the last trading session.
What is the dividend status of SIGILON THERAPEUTICS INC?
SGTX does not pay a dividend.
What is the ChartMill rating of SIGILON THERAPEUTICS INC stock?
SGTX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is SIGILON THERAPEUTICS INC (SGTX) stock traded?
SGTX stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for SIGILON THERAPEUTICS INC?
SIGILON THERAPEUTICS INC (SGTX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for SGTX stock?
SIGILON THERAPEUTICS INC (SGTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.67).
SGTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to SGTX. When comparing the yearly performance of all stocks, SGTX is one of the better performing stocks in the market, outperforming 99.58% of all stocks.
SGTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SGTX. Both the profitability and financial health of SGTX have multiple concerns.
SGTX Financial Highlights
Over the last trailing twelve months SGTX reported a non-GAAP Earnings per Share(EPS) of -9.67. The EPS decreased by -327.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.31 |
SGTX Forecast & Estimates
9 analysts have analysed SGTX and the average price target is 48.28 USD. This implies a price increase of 114.86% is expected in the next year compared to the current price of 22.47.
For the next year, analysts expect an EPS growth of -34.47% and a revenue growth 19.62% for SGTX